Skip to search formSkip to main contentSkip to account menu

alemtuzumab

Known as: MoAb CD52, Anti-CD52 Monoclonal Antibody, alemtuzumab [Chemical/Ingredient] 
A recombinant DNA-derived humanized monoclonal antibody directed against the cell surface glycoprotein, CD52. Alemtuzumab is an IgG1 kappa with human… 
National Institutes of Health

Related topics

Related topics

20 relations
1.2 ML alemtuzumab 10 MG/ML Injection [Lemtrada]Antibody-Dependent Cellular CytotoxicityCD52 geneCD52 protein, human

Broader (3)

Antibodies, Monoclonal, HumanizedAntineoplastic AgentsCD Antigens

Narrower (6)

CampathCampath 1GCampath 1HCampath 1M

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Alemtuzumab induction for retransplantation after primary transplant with alemtuzumab induction
.
BACKGROUND Lymphocyte-depleting induction with alemtuzumab (ALEM) or rabbit antithymocyte-globulin (rATG) is commonly used at… 
2019
2019
Biomarkers of both inflammation and axonal damage are reduced by dimethyl fumarate in a prospective trial of untreated newly diagnosed MS
2010
2010
ALEMTUZUMAB INDUCTION AND TAC/MMF MAINTENANCE SUBSTANTIALLY IMPROVES LONG TERM INSULIN INDEPENDENCE RATES AFTER CLINICAL ISLET TRANSPLANTATION, AND STRONGLY SUPPRESSES BOTH AUTO AND ALLOREACTIVITY…
A.M..J. Shapiro1, C. Toso2, A. Koh3, S.R. Calne4, T. Kin5, D. O’Gorman6, A. Malcolm3, P. Dinyari3, S. Imes3, R. Owen3, N.M… 
2009
2009
Buzz around Campath proof-of-concept trial in MS
2009
2009
Sezary syndrome in relapse after reduced intensity allogeneic transplant successfully treated with donor lymphocyte infusion
Sezary syndrome in relapse after reduced intensity allogeneic transplant successfully treated with donor lymphocyte infusion 
2006
2006
CD52 expression patterns in myeloma and the applicability of alemtuzumab therapy.
Alemtuzumab has been proposed as a therapeutic agent in myeloma. CD52 was detected on plasma cells in 46/106 patients but levels… 
2005
2005
Low frequency of exon 3 PTPN11 mutations in adult de novo acute myeloid leukemia. Analysis of a consecutive series of 173 patients.
A total of 173 samples obtained from adult patients with de novo acute myeloid leukemia (AML) were assayed for exon 3 PTPN11… 
2005
2005
Alemtuzumab in the treatment of relapsed acute lymphoid leukaemia
Dr Laporte and colleagues recently described in Leukemia (September 2004, Vol 18, No. 9) an adult acute lymphoid leukemia (ALL… 
2005
2005
Low-dose intravenous alemtuzumab therapy in pretreated patients affected by chronic lymphocytic leukemia. A single center experience.
We report the efficacy and safety of intravenous low-dose alemtuzumab (10 mg three times weekly for 10 weeks) in 12 patients with… 
2000
2000
Emergence of CD 52-, Phosphatidylinositolglycan-Anchor-Deficient T Lymphocytes After In Vivo Application of Campath-1 H for Refractory B-Cell Non-Hodgkin Lymphoma
CD52 is a phosphatidylinositolglycan (PIG)-anchored glycoprotein (PIG-AP) expressed on normal T and B lymphocytes, monocytes, and…